Rondecabtagene autoleucel (ronde-cel, LYL314)
Aggressive Large B-Cell Lymphoma (Third-line or Later)
Key Facts
About Lyell Immunopharma
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies with the goal of delivering lasting remissions or cures for patients with cancer. The company's approach combines novel CAR constructs, proprietary manufacturing protocols, and T-cell biology insights to generate more potent and persistent T cells. Its lead candidate, ronde-cel, is in pivotal trials for large B-cell lymphoma, while LYL273 is in Phase 1 for metastatic colorectal cancer, representing a significant push into solid tumors. Lyell is a fully integrated company with in-house research, development, and manufacturing capabilities.
View full company profileAbout Lyell Immunopharma
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies with the goal of delivering lasting remissions or cures for patients with cancer. The company's approach combines novel CAR constructs, proprietary manufacturing protocols, and T-cell biology insights to generate more potent and persistent T cells. Its lead candidate, ronde-cel, is in pivotal trials for large B-cell lymphoma, while LYL273 is in Phase 1 for metastatic colorectal cancer, representing a significant push into solid tumors. Lyell is a fully integrated company with in-house research, development, and manufacturing capabilities.
View full company profile